Lineage Cell Therapeutics Inc (AMEX:LCTX)
$ 0.52 -0.0926 (-15.12%) Market Cap: 135.03 Mil Enterprise Value: 105.07 Mil PE Ratio: 0 PB Ratio: 1.75 GF Score: 63/100

Lineage Cell Therapeutics Inc at Solebury Trout KOL Day Transcript

Nov 15, 2019 / 04:00PM GMT
Release Date Price: $0.87 (+8.75%)
Brian M. Culley
Lineage Cell Therapeutics, Inc. - CEO, President & Director

Well, it looks like we can get started. So I'll introduce myself. I'm Brian Culley. I'm the Chief Executive Officer of Lineage Cell Therapeutics. We've got a fantastic day for you today. We've brought 2 individuals who are familiar with our work in the disease areas where we operate. I'll do their introductions in just a moment. After each presentation, there'll be some time for some Q&A. And then I'm just going to have a couple of slides just to get everybody oriented and underway.

We are a public company. I will refer you first to our safe harbor clause, in case I make any forward-looking statements.

So Lineage Cell Therapeutics, many of you, this will be a refresher, but we have 3 clinical stage programs, OpRegen, OPC1 and VAC2, 3 active clinical studies right now. These are supported by, I believe, one of the largest cell therapy intellectual property estates. We have north of 800 patents issued and applications pending. And what we do is we manufacture specific cell types. And then we transplant

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot